Overview

A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use

Status:
Completed

Trial end date:
2018-11-28

Target enrollment:

Participant gender:

Summary

To evaluate the proportion of patients with undetectable HCV RNA at 12 weeks post end of treatment (SVR12) following sofosbuvir/GS-5816 therapy for 12 weeks in people with chronic HCV infection and recent injection drug use.

Phase:

Phase 2

Details

Lead Sponsor:

Kirby Institute

Treatments:

Sofosbuvir
Velpatasvir